Modification of soluble immunological parameters during treatment with interleukin-2

I. Abbate, M. Correale, M. D. Musci, M. Guida, C. D. Dragone, M. De Santis, M. De Lena

Research output: Contribution to journalArticlepeer-review


In the present study we tested numerous soluble immunological parameters (soluble Interleukin 2 receptor, Beta 2 microglobulin, Neopterin, soluble CD8 antigen, gamma Interferon and alpha Tumor Necrosis Factor) in sera obtained from 18 advanced cancer patients during subcutaneous treatment with recombinant Interleukin 2. The treatment cycles consisted of a dose of 9 x 106 IU/m2 twice daily for 2 days followed by 1.8 x 106 IU/m2 twice daily for 5 days/week during 6 weeks. Even before therapy, neoplastic patients had higher levels of soluble Interleukin 2 receptor than a group of healthy subjects. Moreover, basal soluble CD8 antigen levels showed significant differences (p <0.01) in patients with different clinical responses (responders and non-responders). During treatment we observed a fast increase (in the first or second week) of all parameters considered; soluble Interleukin 2 receptor and soluble CD8 antigen were the markers that were best related to the course of immunotherapy. In conclusion, monitoring recombinant Interleukin 2 immunotherapy with immunological parameters in serum seems to be of interest. However, more data are necessary to confirm the real value of the single markers.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalInternational Journal of Biological Markers
Issue number4
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Biochemistry
  • Immunology


Dive into the research topics of 'Modification of soluble immunological parameters during treatment with interleukin-2'. Together they form a unique fingerprint.

Cite this